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MaHypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease for which prevalence in the general
population has not been completely resolved. For the past 20 years, most data have supported the occurrence of HCM
at about 1 in 500. However, the authors have interrogated a number of relevant advances in cardiovascular medicine,
including widespread fee-for-service genetic testing, population genetic studies, and contemporary diagnostic imaging,
as well as a greater index of suspicion and recognition for both the clinically expressed disease and the gene-positive–
phenotype-negative subset (at risk for developing the disease). Accounting for the potential impact of these initiatives
on disease occurrence, the authors have revisited the prevalence of HCM in the general population. They suggest that
HCM is more common than previously estimated, which may enhance its recognition in the practicing cardiovascular
community, allowing more timely diagnosis and the implementation of appropriate treatment options for many patients.
(J Am Coll Cardiol 2015;65:1249–54) © 2015 by the American College of Cardiology Foundation.H ypertrophic cardiomyopathy (HCM) is aclinically and genetically heterogeneousdisorder. It is characterized most com-
monly by left ventricular (LV) hypertrophy, with a
range of potential outcomes including heart failure
and sudden cardiac death, but also survival to normal
life expectancy (1,2). HCM is a global disease (3) and is
considered 1 of the most common genetic heart disor-
ders, with an estimated prevalence of 1 in 500 people
(4). Recognition of HCM is important, both for
providing treatment and prevention strategies and
in triggering the initiation of clinical and genetic sur-
veillance of family members. In this commentary, we
make the argument that HCM, including patients
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dition than previously thought.
REPORTED PREVALENCE OF HCM
The estimated prevalence of HCM of 1 in 500 is based
on data originally collected almost 20 years ago in the
landmark CARDIA (Coronary Artery Risk Develop-
ment in Young Adults) cohort study, which reported
standard echocardiographic analyses in 4,111 unre-
lated people 23 to 35 years of age (4). CARDIA was a
biracial cohort established to longitudinally investi-
gate life-style and other variables that inﬂuence the
evolution of coronary risk factors during young
adulthood. Subjects were randomly selected from thetitute, Sydney, Australia; ySydney Medical School,
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1250general population in community-based ur-
ban centers and census tracts (4).
This prevalence estimate was subse-
quently supported by a number of U.S. and
international studies, including from China,
Japan, and East Africa, with diverse study
designs and variable ages of subjects, geog-
raphy, and racial/ethnic composition (4–10)
(Table 1). However, advances in HCM since
the publication of these studies, including amore robust clinical experience, enhanced under-
standing of the underlying molecular and genetic
substrate, the implementation of contemporary fam-
ily screening, and more sensitive diagnostic cardiac
imaging, contribute to the notion that the prevalence
of this disease may have been underestimated.
GENETIC POPULATION STUDIES
Perhaps the most compelling avenue of evidence that
supports the revised prevalence estimate for HCM,
and the principle that this disease is more common
than previously regarded, comes from the discovery of
its molecular basis and the subsequent implementa-
tion of genetic testing, after publication of the CARDIA
study almost 20 years ago (4). At least 11 genes have
now been identiﬁed, which primarily encode more
than 1,500 cardiac sarcomere and sarcomere-related
single-nucleotide mutations, critical for the basic
contractile function of the heart (Figure 1) (11,12).
Importantly, sarcomere proteinmutations known to
cause HCM are unexpectedly common in the general
population. In 2012, Seidman and colleagues reported
a relatively high frequency of pathogenic (disease-
causing) mutations in a general community-based
study designed to assess the burden of structural car-
diovascular disease conferred by rare variants. In that
unique investigation, 3,600 participants of both sexes
(30 to 84 years of age) were studied, including 1,637
unrelated subjects in the offspring cohort of the Fra-
mingham Heart Study and 1,963 unrelated subjects1 Prior Estimates of HCM Prevalence With Echocardiography i
hor (Ref. #) Year N
Age
(yrs) % Male
Maximal LV
Thickness (mm
al. (4) 1995 4,111 25–35 71 17  2
al. (6) 1987 1,584 47* 76 17  3
al. (8) 1999 15,137 57* 48 21  4
al. (9) 2004 3,501 60 50 21  3
l. (5) 2004 8,080 52 69 17  6
al. (10) 2006 6,680 55 68 21  0.4
nts with HCM. †Derived from the Strong Heart Study, with subjects from Ariz
¼ Coronary Artery Risk Development in Young Adults; HCM ¼ hypertrophic cfrom the JacksonHeart Study cohort (13). Screening the
principal 8 HCM-causing sarcomere protein genes
identiﬁed 1 or more rare nonsynonymous sarcomere
variants (i.e., minor allele frequency <1%) in 11.2%
of the general population, of which 0.6% were
considered disease causing using stringent criteria
for pathogenicity (Harvard Partners criteria) (12,14).
It is possible that others of these variants could prove
to be pathogenic (Figure 1).
Therefore, on the basis of these data, the minimal
prevalence of HCM gene carriers could be estimated
at 1 in 200 people or greater, and therefore 2.5-fold
more common than reported in the original HCM
phenotype-based echocardiographic CARDIA study
(4). Although all gene carriers may not develop clin-
ical HCM, the high frequency of HCM-causing path-
ogenic mutations strongly suggests a prevalence
exceeding that reported in the CARDIA study (4).
RECOGNITION OF GENOTYPE-POSITIVE–
PHENOTYPE-NEGATIVE PATIENTS
The availability of commercial genetic testing for
HCM and recent advances in next-generation
sequencing technologies are contributing to more
comprehensive and less costly genetic testing. The
value of a genetic diagnosis in an HCM family is
immeasurable, allowing asymptomatic relatives to
undergo predictive genetic testing to identify their
carrier status, as well as contributing to an expansion
of theHCMdisease spectrum (15). Consequently, a new
HCM subgroup has been identiﬁed, that is, asymp-
tomatic gene carriers without LV hypertrophy, known
as “genotype-positive–phenotype-negative” (Gþ P)
(16–22). Such Gþ P subjects without the HCM
phenotype were not identiﬁable or present in studies
such as CARDIA, before the genetic era for HCM (11,12),
which relied on echocardiographic diagnosis with
recognition of LV wall thickening (4). Although these
genetically affected subjects without clinical evidence
of disease cannot be included in prevalence estimatesn 6 Populations
)
Reported
Prevalence (%) Study Subjects
0.17 Random sampling from urban general population
(CARDIA study)
0.17 Annual health examinations
0.19 Mobile echocardiography in rural communities
0.23 American Indian tribal communities†
0.16 Random sample from 9 communities in China
0.19 East African (Tanzanian) district regional hospitals
ona, Oklahoma, North Dakota, and South Dakota.
ardiomyopathy; LV ¼ left ventricular.
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1251on the basis of the HCM phenotype, they nonetheless
represent a distinct subgroup at some risk for devel-
oping disease, requiring ongoing assessment and
possible management considerations.
It should be emphasized that the natural history of
this group of family members over time remains
largely unresolved and that caution should be exer-
cised before regarding such subjects as harboring
a true disease state requiring restrictions in life-
style, such as exclusion from competitive sports or
employment (23). Gþ P status would add consi-
derably to the prevalence of HCM. As evidence
for this assertion, a review of genetically tested
families with HCM enrolled in the Australian GeneticFIGURE 1 Genomics and Prevalence of HCM
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CLINICAL SCREENING OF HCM FAMILIES
Not accounted for in the CARDIA and other study
designs are the multiple clinically expressed relatives
in most HCM families (1,2,11,12,25,26). Although HCM
is inherited as an autosomal-dominant trait, with
ﬁrst-degree relatives having a 50% chance of inher-
iting the disease, the CARDIA study included only a
speciﬁc adult age group, and most importantly, none
of the 4,111 participants were related (4). Given thatinding
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1252HCM is a familial disease, this is another source of
underestimating the true prevalence of HCM in the
general population.
ENHANCED DETECTION OF HCM PHENOTYPE
BY ADVANCED IMAGING
CARDIA and all other HCM clinical prevalence stu-
dies used conventional 2-dimensional echocar-
diography to identify the HCM phenotype (27).
However, cardiac magnetic resonance (CMR) imaging
has recently emerged as a more precise diagnostic
tool in some patients with HCM (28–31) (Figure 2).
Although echocardiography remains the cornerstone
of cardiac assessment in HCM, recent comparativeages Demonstrating Diversity of the HCM Phenotype
B
D
as of hypertrophy within the left ventricular chamber not reliably
sional echocardiography (i.e., “echo-blind”), potentially responsible
f hypertrophic cardiomyopathy (HCM). (A) Segmental hypertrophy of
he anterolateral free wall (asterisk), sparing the ventricular septum.
lized to the left ventricular apex (asterisk), that is, apical HCM.
onﬁned to the posterior (inferior) septum (asterisk). (D) Crista
uscle (arrowheads), a prominent right ventricular structure that in-
anterior ventricular septum and can be inappropriately included in the
l thickness, resulting in overdiagnosis of HCM. With cardiac magnetic
ging, the crista supraventricularis is recognized moving away from the
le, leaving a small blood pool between the crista and septum (arrow)
accurate delineation of the endocardial border of the septum
ventricle; RV ¼ right ventricle; VS ¼ ventricular septum.studies have shown CMR to have the high-resolution
tomographic imaging capability for identifying not
only myriad patterns of LV wall thickening but also
the HCM phenotype in some patients in whom
hypertrophy is conﬁned to the apical, anterolateral,
or posterior (inferior) septal regions of the LV cham-
ber, often not reliably visualized with standard
echocardiographic cross-sectional planes (28,29,31).
Furthermore, CMR is also capable of clarifying diag-
nosis when the extent of LV hypertrophy is consid-
ered borderline or ambiguous by echocardiography
(Figure 2) (1,2,28,29,31). Patients with such morpho-
logic imaging considerations are unavoidably
excluded from current prevalence ﬁgures, thereby
further supporting the likelihood that clinically
expressed HCM was underestimated in the earlier
echocardiographic era (27) and in HCM population
studies (4–10).
IMPLICATIONS AND CONCLUSIONS
Over the past 10 to 20 years, investigators committed
to HCM have been able to rapidly assemble large pa-
tient cohorts with ease, exceeding expectations on
the basis of earlier perceptions of disease frequency.
Indeed, HCM would now appear to be the most
common of the genetic heart diseases. With these
clinical intuitions as a starting point, we have con-
structed a viewpoint on the basis of contemporary
principles and data, which supports the principle that
HCM may well be more common than the prevalence
of 1 in 500 initially established by the CARDIA study
(4) but now potentially outdated.
Several avenues of evidence support this hypoth-
esis: 1) pathogenic sarcomere genes are more common
in the general population than previously thought;
2) genetic testing has deﬁned a new subset of patients
without clinical expression and LV hypertrophy
(Gþ P); 3) recognition of some HCM phenotypes
is enhanced by advanced imaging (i.e., CMR); and
4) prior prevalence studies do not account for the
familial nature of the disease (Central Illustration).
When these contemporary clinical and genetic
principles are considered, it is possible to make the
case for a revised estimate of the combined preva-
lence of clinically expressed HCM and gene carriers
(at risk for developing the disease phenotype), which
we place at about 1 in 200 (32). This revised preva-
lence estimate is based on the assimilation of diverse
and currently available data. It is unlikely that a
comprehensive, large, population-based, epidemio-
logically sound study with genetic testing and echo-
cardiographic and CMR imaging for the purpose of
establishing the prevalence of HCM will occur.
CENTRAL ILLUSTRATION Factors Contributing to the Revised Estimate for the Prevalence of HCM
1:500 (0.2%)
CARDIA Current HCM Prevalence
Advanced Imaging (CMR) 
Identifies Some Echo-Negative Patients
Autosomal Dominant Familial Inheritance
with Multiple Affected Relatives
Gene (+)
Phenotype (-)
Gene Carriers
Pathogenic Sarcomere Mutations
(general population genetics)
Revised Estimate of HCM Prevalence
0.6%
>1:500
Semsarian, C. et al. J Am Coll Cardiol. 2015; 65(12):1249–54.
The initial estimate of the prevalence of hypertrophic cardiomyopathy (HCM) came largely from the CARDIA (Coronary Artery Risk
Development in Young Adults) study, which relied on echocardiographic identiﬁcation of probands. Among the factors contributing to the
revised estimate of more common than 1 in 500 were the identiﬁcation of gene carriers who are negative for the HCM phenotype; enhanced
clinical identiﬁcation of the HCM phenotype with advanced imaging; recognition that because of the autosomal-dominant inheritance pattern,
multiple relatives of probands (and carriers) would be affected by HCM; and recognition that up to 0.6% of the population may carry
HCM-causing sarcomere mutations. CMR ¼ cardiac magnetic resonance.
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1253Recognition of a higher, more accurate prevalence
ﬁgure for HCM may be important to the patient
population and practicing cardiovascular community
for a number of reasons. If HCM is more common
and has higher visibility in the medical conscious-
ness, it is more likely that this disease will be
considered in cardiology practice. Increased aware-
ness and recognition of HCM among cardiologists
and allied health professionals will, in turn, enhance
the overall index of suspicion and increase the fre-
quency of diagnosis in family members and in the
general population. This will promote more timely
and contemporary treatment options for many
patients, with the capability of reducing adult
HCM-related mortality to 0.5%/year, similar to that
expected in the general U.S. population (33).Together, all these considerations ultimately dispel
the historical myth that HCM is a rare and untreat-
able genetic heart disease, which has in the past
suppressed its visibility, recognition, and under-
standing within cardiovascular medicine.
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